Could Neprilysin Be Already Inhibited by BNP in the LIFE Trial?-Reply.

JAMA Cardiol

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Published: June 2022

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2022.0787DOI Listing

Publication Analysis

Top Keywords

neprilysin inhibited
4
inhibited bnp
4
bnp life
4
life trial?-reply
4
neprilysin
1
bnp
1
life
1
trial?-reply
1

Similar Publications

Novel Therapies for Right Ventricular Failure.

Curr Cardiol Rep

January 2025

Pediatric Advanced Heart Failure and Heart Transplant Program, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS, USA.

Purpose Of Review: Traditionally viewed as a passive player in circulation, the right ventricle (RV) has become a pivotal force in hemodynamics. RV failure (RVF) is a recognized complication of primary cardiac and pulmonary vascular disorders and is associated with a poor prognosis. Unlike treatments for left ventricular failure (LVF), strategies such as adrenoceptor signaling inhibition and renin-angiotensin system modulation have shown limited success in RVF.

View Article and Find Full Text PDF

Unlabelled: Alzheimer's disease (AD) is a progressive neurological condition that causes brain shrinkage and cell death. This study aimed to identify the role of the NORAD/miR-26b-5p axis in AD. StarBase was used to examine the binding sequences of miR-26b-5p to LncRNA NORAD or its target genes, which were verified by a double luciferase reporter assay.

View Article and Find Full Text PDF

Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications.

Front Pharmacol

December 2024

Department of Orthodontics, State Key Laboratory of Oral Diseases, West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China.

Neprilysin (NEP), a zinc-dependent membrane-bound metallopeptidase, regulates various bioactive peptides, particularly in kidneys, vascular endothelium, and the central nervous system. NEP's involvement in metabolizing natriuretic peptides, insulin, and enkephalins makes it a promising target for treating cardiovascular and Alzheimer's diseases. Several NEP inhibitors, such as sacubitril and omapatrilat, have been approved for clinical use, which inhibit NEP activity to prolong the bioactivity of beneficial peptides, thereby exerting therapeutic effects.

View Article and Find Full Text PDF

Importance: Angiotensin receptor-neprilysin inhibition (ARNI) improves mortality among patients with heart failure with reduced ejection fraction (HFrEF), ie, those with an EF of 40% or less.

Objective: To describe national longitudinal trends in ARNI prescribing patterns among hospitalized patients with HFrEF.

Design, Setting, And Participants: Using data from the Get With The Guidelines-Heart Failure (GWTG-HF) registry, hospitalized patients with HFrEF at 614 participating hospitals were identified.

View Article and Find Full Text PDF
Article Synopsis
  • Home time, or the duration patients with cardiovascular disease spend alive outside of healthcare institutions, is an essential aspect of recovery, particularly for heart failure (HF) patients, yet insufficiently studied in India where HF rates are increasing.
  • Current literature falls short in identifying hospital-level trends and predictors of home time, which complicates the development of personalized care strategies to enhance health outcomes, functional status, and reduce hospitalization risks.
  • While guideline-directed medical therapy, especially sacubitril/valsartan (an angiotensin receptor neprilysin inhibitor), is well-supported for improving life quality and reducing HF-related hospitalizations, its use remains low, indicating a critical need for better integration into clinical practice to improve patient recovery and home time post
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!